Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
The report was published on 06 de novembro de 2026 às 14:40 by CNBC and is part of the World news coverage.
What other outlets are saying
- CNBC: Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- CBC: Moderna's mRNA flu and flu-COVID combo vaccines have been approved by Health Canada
- WSJ: Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes
- WSJ: Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes
- MarketWatch: Moderna’s stock jumps after biotech raises sales outlook
Quick answers
Who reported this story?
It was first reported by CNBC on 06 de novembro de 2026 às 14:40.
What is the category?
It is filed under World news on Rio Warzone News.
